The window between December 2025 and May 2026 produced an unusually validation-heavy crop of process analytical technology papers. The common thread across them is not a new sensor or a flashy algorithm but the question that decides whether any of this gets into a regulated production line: what does it take to build a model that survives qualification, inspection, and routine use?

Below are six papers from that window - three reviews and three methods studies - that any chemometrician, PAT engineer, or QA reviewer building or auditing a spectroscopic application should have on their desk. The shortlist is constrained to peer-reviewed work in journals an inspector will recognise.

Lean chemometrics: making models cheaper to validate

Rish, Henson, and Rehrauer’s Lean Chemometrics in Spectroscopic Process Analytical Technology in the Journal of Chemometrics (January 2026) is the most consequential of the group for industrial PAT teams. The authors argue that conventional multivariate data analysis demands calibration sets that are expensive in time, material, and operator hours, and that this cost - not algorithmic novelty - is the gating factor for spectroscopic PAT adoption in pharma. The paper sets out reduced-data calibration approaches that aim to keep performance metrics defensible while shrinking the experimental footprint. A companion piece by the same authors, Supporting Process Analytical Technology in Pharmaceutical Manufacturing With Lean Chemometrics, appeared one month later and works the framing through manufacturing-context examples.

For teams designing a model lifecycle under ICH Q14 and the related Q2(R2) revisions, the practical question is whether a leaner calibration can hold up against analytical-target-profile expectations now applied at review. The two papers do not resolve that, but they map the trade space.

Bioprocess Raman: simpler models are easier to defend

In Biotechnology and Bioengineering, Borg and colleagues’ Less Is More: Practical Insights Into Multivariate Regression Models for Raman Spectroscopy in Bioprocess Monitoring takes a similar position from a bioprocess angle. The review pushes back against the idea that more complex chemometric pipelines are inherently better, and lays out a workflow oriented to robustness, transparency, and maintainability - all three of which directly affect how a model is validated and how often it has to be revalidated.

It is useful reading alongside Spectrane’s earlier coverage of validating a chemometric model for GMP use and the recent literature on calibration transfer between instruments: together they describe a model small enough to understand, defensible against challenge runs, and portable enough to move from a development instrument to a production one without a fresh full validation.

A review of continuous-downstream PAT for mAbs

Carvalho and co-authors’ Review on Quantitative Process Analytical Technology for Continuous Downstream Processing of Monoclonal Antibodies (Biotech. Bioeng., December 2025) is the most explicit on the gap between research-scale and GMP-scale validation. The authors note that the bulk of quantitative PAT for mAb downstream to date has been demonstrated at small scale, without the operational record needed to justify use in pilot or manufacturing-scale GMP processes. Real-time release testing for biologics is a long-standing target; this review is a sober look at the published evidence base supporting it.

PAT plus machine learning, beyond the bioreactor

Two methods papers in this window show PAT used as the spectroscopic front end for machine-learning models, with explicit validation metrics rather than a vague claim of “AI-powered” monitoring.

Lee and colleagues’ Liposome Particle Size Prediction by In-Line PAT-Integrated Machine Learning in Small Methods (May 2026) reports an in-line model that predicts liposome particle size with a root-mean-square error of 7.18 nm in calibration and 7.53 nm in generalisation testing. Interpretability is built in via physicochemical membrane characteristics rather than left as an afterthought - which matters when the model has to be defended in a regulatory dossier.

Jesubalan, Sharma, and Rathore’s MOO-based implementation of process analytical technology framework: Protein refolding as a case study in AIChE Journal (March 2026) compares a multiple-partial-least-squares statistical-process-control chart against a one-dimensional convolutional neural network for the same refolding process. Cross-comparison of a classical PAT model against a deep-learning one on identical data is exactly the kind of head-to-head a quality unit needs to see before accepting either.

Solid dosage forms: terahertz for absence of crystallinity

Outside the bioreactor, Leung, Kuchler, and Zeitler’s Detecting absence of crystallinity in solid dosage forms with at-line terahertz process analytical technology in the International Journal of Pharmaceutics (January 2026) is a useful counterpoint to the spectroscopic-only literature. Amorphous solid dispersions need a method that can confirm the absence of detectable crystallinity, and the paper positions at-line terahertz as a candidate. For real-time release frameworks aimed at amorphous formulations, this is a method worth tracking through the next validation round.

Reading the field

Six papers do not amount to a trend; the more interesting observation is that lean calibration, simpler models, explicit validation metrics, and head-to-head comparisons keep recurring across very different application areas. That is what the methodology literature looks like when an industry is moving from feasibility to qualification at scale. For the longer view of the regulatory framing, the first five years under USP chapter 858 remains the most useful reference.